{
    "code": "52027902",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52027902",
    "time": "2023-01-27 04:10:03",
    "許可證字號": "衛部藥輸字第027902號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "114\/07\/27",
    "發證日期": "109\/07\/27",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原登錄字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA05202790208",
    "中文品名": "銳虎持續性藥效錠15毫克",
    "英文品名": "RINVOQ Extended-Release Tablets 15 mg",
    "適應症": "1.類風濕性關節炎：治療患有中至重度活動性類風濕性關節炎且對至少一種疾病緩解型抗風濕藥物(DMARDs)無法產生適當治療反應或無法耐受之成人病人。可用於單一療法或與methotrexate合併使用。\r\n2.乾癬性關節炎：治療患有活動性乾癬性關節炎且對至少一種疾病緩解型抗風濕藥物(DMARDs)無法產生適當治療反應或無法耐受的成人病人。RINVOQ可用於單一療法或與非生物製劑疾病緩解型抗風濕藥物(non-biologic DMARDs)合併使用。\r\n3.僵直性脊椎炎：治療曾對非類固醇抗發炎藥物(NSAID)反應不佳或耐受性不良的活動性僵直性脊椎炎成人病人。\r\n4.異位性皮膚炎：治療患有中度至重度異位性皮膚炎，適合全身性療法的成人及12歲(含)以上青少年。",
    "劑型": "121持續性藥效錠",
    "包裝": "2-1000錠PVC\/PE\/PCTFE鋁箔盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "管制藥品分類級別": "",
    "藥品分類": "新成分",
    "監視期限": "114\/07\/27",
    "主成分略述": "Upadacitinib Hemihydrate",
    "限制項目": "02輸　入 1D須執行風險管理計畫 5E已執行國內臨床試驗",
    "申請商名稱": "6401101591  瑞士商艾伯維藥品有限公司台灣分公司",
    "申請商地址": "台北市中山區民生東路三段49號及51號15樓",
    "主製造廠": [
        {
            "製造廠名稱": "FIE0075000  AbbVie Ireland NL B.V.",
            "製造廠廠址": "Manorhamilton Road,Sligo,Ireland",
            "製造廠公司地址": "",
            "製造廠國別": "IRELAND",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "6132061151  裕利股份有限公司",
            "製造廠廠址": "桃園市大園區和平里1鄰開和路91號",
            "製造廠公司地址": "",
            "製造廠國別": "TAIWAN",
            "製程": "二級包裝廠(委託貼標及置入仿單)"
        },
        {
            "製造廠名稱": "FIT0347000  ABBVIE S.R.L.",
            "製造廠廠址": "S.R. 148 PONTINA KM 52,SNC-CAMPOVERDE DI APRILIA (LT) 04011 ITALY",
            "製造廠公司地址": "",
            "製造廠國別": "ITALY",
            "製程": "包裝"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200090300",
            "成分名稱": "Upadacitinib Hemihydrate",
            "含量描述": "(Corresponds to upadacitinib 15mg on an anhydrous basis)",
            "含量": "15.4000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "03_TW-RINVOQ Leaflet_AD 15mg_中文仿單_Final_clean_20211119-110-11-25.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027902&Seq=004&Type=9"
        },
        {
            "title": "TW-RINVOQ Carton_銳虎持續性藥效錠15毫克_外盒-109-08-18.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027902&Seq=002&Type=8"
        },
        {
            "title": "TW-RINVOQ Blister_銳虎持續性藥效錠15毫克_鋁箔-109-08-18.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027902&Seq=001&Type=8"
        }
    ]
}